The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2025 | The potential of Glofit-GemOx as a new standard of care in R/R DLBCL
Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, comments on the potential of glofitamab plus gemcitabine-oxaliplatin (Glofit-GemOx) to become the new standard of care (SoC) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Prof. Sureda highlights findings from the Phase III STARGLO trial (NCT04408638), which demonstrated significant improvements in overall response rate (ORR), complete remission (CR) rate, and overall survival (OS) with Glofit-GemOx when compared to the rituximab plus GemOx regimen. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So STARGLO was this pivotal Phase III prospective clinical trial that randomized 2:1 Glofitamab-GemOx in front of rituximab-GemOx, which has been and it is still the standard of care as second-line treatment strategies or eventually later on for patients with diffuse large B-cell lymphoma that relapse or are primary refractory and that are not candidates for an autologous stem cell transplant...
So STARGLO was this pivotal Phase III prospective clinical trial that randomized 2:1 Glofitamab-GemOx in front of rituximab-GemOx, which has been and it is still the standard of care as second-line treatment strategies or eventually later on for patients with diffuse large B-cell lymphoma that relapse or are primary refractory and that are not candidates for an autologous stem cell transplant.
We know that R-GemOx is not an excellent strategy because the long-term results are quite poor and the capacity to achieve for this regimen to achieve a complete remission is quite low.
So the STARGLO demonstrated that substituting Rituximab by Glofitamab, which is a bispecific monoclonal antibody targeting CD20 and CD3, able to significantly improve the overall response rate, complete remission rate, and that was translated into significantly better overall survival.
So I think that this is going to change probably the standard of care, at least from a theoretical point of view. And of course, Glofit-GemOx is going to be more accessible in the long run than CAR T-cells, which might be, let’s say a kind of competing strategy in many places for this specific subgroup of patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Honoraria: Takeda, BMS/Celgene, MSD, Janssen, Amgen, Novartis, Gilead Kite, Sanofi, Roche, Alexion; Consultancy: Takeda, BMS/Celgene, Novartis, Janssen, Gilead, Sanofi; Speaker’s Bureau: Takeda; Research Support: Takeda, BMS/Celgene; Non-profit organizations: Presidency of the GETH-TC, Presidency of the EBMT.
